cancer, Life Sciences, Stem Cells

Genzyme’s Mozobil Gets European Approval

Ryan McBride 8/5/09

Cambridge, MA-based biotech Genzyme (NASDAQ:GENZ) reports that the firm has won European marketing approval for plerixafor (Mozobil) for injection in patients with two types of blood cancers—lymphoma and multiple myeloma—who need blood-forming stem cell transplants. The European Commission granted approval of plerixafor to be used in combination with granulocyte-colony stimulating factor (G-CSF) to boost the mobilization of stem cells in blood cancer patients, according to Genzyme. Plerixafor was cleared for sales in the U.S. last December.

Ryan McBride is Xconomy's correspondent. You can reach him at rmcbride@xconomy.com, or follow him on Twitter at http://twitter.com/Ryan_McBride.